334 related articles for article (PubMed ID: 29736852)
21. Erdheim-Chester disease: CT findings of thoracic involvement.
Brun AL; Touitou-Gottenberg D; Haroche J; Toledano D; Cluzel P; Beigelman-Aubry C; Piette JC; Amoura Z; Grenier PA
Eur Radiol; 2010 Nov; 20(11):2579-87. PubMed ID: 20563815
[TBL] [Abstract][Full Text] [Related]
22. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B
Front Immunol; 2022; 13():918613. PubMed ID: 35874752
[TBL] [Abstract][Full Text] [Related]
23. Erdheim-Chester disease with an 18F-fluorodeoxyglucose-avid breast mass and BRAF V600E mutation.
Furuta T; Kiryu S; Yamada H; Hosoi M; Kurokawa M; Morikawa T; Shibahara J; Ohtomo K
Jpn J Radiol; 2014 May; 32(5):282-7. PubMed ID: 24531980
[TBL] [Abstract][Full Text] [Related]
24. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.
Yuen CA; Bao S; Aung MS; Shishodia R; Kong XT
Per Med; 2024; 21(2):71-78. PubMed ID: 38275171
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary manifestations of Erdheim-Chester disease: clinical characteristics, outcomes and comparison with Langerhans cell histiocytosis.
Wang JN; Wang FD; Sun J; Liang ZY; Li J; Zhou DB; Tian X; Cao XX
Br J Haematol; 2021 Sep; 194(6):1024-1033. PubMed ID: 34423426
[TBL] [Abstract][Full Text] [Related]
26. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
[TBL] [Abstract][Full Text] [Related]
27. Erdheim-Chester disease involving the breast--a rare but important differential diagnosis.
Guo S; Yan Q; Rohr J; Wang Y; Fan L; Wang Z
Hum Pathol; 2015 Jan; 46(1):159-64. PubMed ID: 25454479
[TBL] [Abstract][Full Text] [Related]
28. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease.
Cao XX; Niu N; Sun J; Cai H; Wang FD; Wang YN; Duan MH; Zhou DB; Li J
Orphanet J Rare Dis; 2019 Jan; 14(1):11. PubMed ID: 30630516
[TBL] [Abstract][Full Text] [Related]
29. A case of Erdheim-Chester disease with spinal cord compression and sphenoid sinus involvement.
Bunaux K; Sevestre H; Emile JF; Capel C; Chenin L; Peltier J
Neurochirurgie; 2018 Dec; 64(6):439-441. PubMed ID: 30274919
[TBL] [Abstract][Full Text] [Related]
30. Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester disease? A case-based review of a rare and difficult to diagnose disorder.
Bosco J; Allende A; Varikatt W; Lee R; Stewart GJ
Intern Med J; 2015 Mar; 45(3):348-51. PubMed ID: 25735579
[TBL] [Abstract][Full Text] [Related]
31. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
[TBL] [Abstract][Full Text] [Related]
32. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].
Liu T; He TH; Niu N; Li J; Zhou DB; Cao XX
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):752-756. PubMed ID: 34753230
[No Abstract] [Full Text] [Related]
34. [Erdheim-Chester disease : a case report].
Delporte G; Delcorde I; Rorive A; Jeugmans A; Moonen M; Koopmansch B; Moonen G; Delvenne P
Rev Med Liege; 2020 Apr; 75(4):213-217. PubMed ID: 32267108
[TBL] [Abstract][Full Text] [Related]
35. Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.
Mazor RD; Manevich-Mazor M; Kesler A; Aizenstein O; Eshed I; Jaffe R; Pessach Y; Goldberg I; Sprecher E; Yaish I; Gural A; Ganzel C; Shoenfeld Y
BMC Med; 2014 Dec; 12():221. PubMed ID: 25434739
[TBL] [Abstract][Full Text] [Related]
36. BRAF V600E mutation in pediatric intracranial and cranial juvenile xanthogranuloma.
Techavichit P; Sosothikul D; Chaichana T; Teerapakpinyo C; Thorner PS; Shuangshoti S
Hum Pathol; 2017 Nov; 69():118-122. PubMed ID: 28504206
[TBL] [Abstract][Full Text] [Related]
37. An effective treatment in Erdheim Chester disease: vemurafenib: a case report.
Bozan E; Darçın T; Yaman S; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
J Med Case Rep; 2023 Oct; 17(1):426. PubMed ID: 37821987
[TBL] [Abstract][Full Text] [Related]
38. Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports.
Qiao J; Ma R; Peng X; He W
World J Surg Oncol; 2023 Jul; 21(1):233. PubMed ID: 37525276
[TBL] [Abstract][Full Text] [Related]
39. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.
Hyman DM; Diamond EL; Vibat CR; Hassaine L; Poole JC; Patel M; Holley VR; Cabrilo G; Lu TT; Arcila ME; Chung YR; Rampal R; Lacouture ME; Rosen N; Meric-Bernstam F; Baselga J; Kurzrock R; Erlander MG; Janku F; Abdel-Wahab O
Cancer Discov; 2015 Jan; 5(1):64-71. PubMed ID: 25324352
[TBL] [Abstract][Full Text] [Related]
40. Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review.
Aggarwal A; Taychert M; Hasanin L; Doll D; Basuino MG; Hasanein H
Oncology (Williston Park); 2023 Jul; 37(7):298-302. PubMed ID: 37499251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
